Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 1.00 |
| ▸ | GRIK2 | Q13002 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7786187 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2GRM2GRM3SLC1A1 | |
| SCHEMBL7703039 | 1.00 | GRIK1 (1.00) | GRIK1GRIK2GRM2GRM3SLC1A1 | |
| SCHEMBL7450346 | 0.85 | GRIK1 (0.73) | GRIK1GRIK2SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL23138631 | 0.85 | GRIK1 (0.73) | GRIK1GRIK2SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL23139425 | 0.76 | GRIK1 (0.60) | GRIK1GRIK2HTR2A | |
| SCHEMBL23139426 | 0.73 | GRIK1 (0.57) | GRIK1GRIK2GRM2GRM3SLC1A1 | |
| SCHEMBL7781119 | 0.73 | GRIK1 (1.00) | GRIK1GRIK2SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL24814159 | 0.72 | GRIK1 (0.56) | GRIK1GRIK2HTR2A | |
| SCHEMBL29178391 | 0.72 | GRIK1 (0.56) | GRIK1GRIK2HTR2A | |
| SCHEMBL133913 | 0.71 | SLC1A1 (1.00) | GRIK1GRM2GRM3SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002014261-A2 | 4-SUBSTITUTED D-GLUTAMIC ACID DERIVATIVES FOR USE AS ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |